HealthQuill Drugs
The death toll in the Ebola outbreak in the Democratic Republic of Congo (DRC) and Uganda climbed to 130 as the WHO stated the situation as “deeply disturbing.”
Drugs Health Pharma

Ebola outbreak deaths at 130, WHO says situation ‘deeply concerning’

The death toll in the Ebola outbreak in the Democratic Republic of Congo (DRC) and Uganda climbed to 130 as the WHO stated.

Read More
The WHO has declared an Ebola outbreak in the Democratic Republic of Congo (DRC) and Uganda as a public health emergency following the death of 80 people linked to the disease and stated the risk was high that it could spread to neighbouring nations
Drugs Health Pharma

WHO declares Ebola outbreak in Congo, Uganda, as a public health emergency

The WHO has declared an Ebola outbreak in the Democratic Republic of Congo (DRC) and Uganda as a public health emergency following the.

Read More
The Vietnam War marked a turning point in wartime psychiatry. Many veterans returned to a divided and often unsupportive society. They reported persistent nightmares, flashbacks, emotional numbness, hypervigilance, and difficulty reintegrating into civilian life.
Drugs Health Opinion

War in the mind: Post traumatic stress disorder and human resilience

The Vietnam War marked a turning point in wartime psychiatry. Many veterans returned to a divided and often unsupportive society. They reported persistent.

Read More
Novartis AG’s treatment for malaria in infants and newborns weighing between two and five kilograms has been approved in Switzerland, and eight African nations are set to follow.
Drugs Health

WHO clears malaria treatment designed for newborns and infants

Swati Sri April 25, 2026: The World Health Organisation (WHO), prequalified the first anti malaria treatment developed specifically for newborns and young infants.

Read More
Novartis AG will buy a US-based private biotech company, Excellergy, Inc, for $2 billion to expand its allergy portfolio.
Drugs Health Pharma

Novartis AG to acquire Exellergy for $2 billion, expand allergy portfolio

Novartis AG will buy a US-based private biotech company, Excellergy, Inc, for $2 billion to expand its allergy portfolio.

Read More
Merck & Co will buy Terns Pharmaceuticals, Inc., a clinical-stage oncology company, for $6.7 billion to pocket an investigational drug to treat a type of blood cancer, according to a statement.
Drugs Health Pharma

Merck to buy Terns for $6.7 billion as Keytruda drug patent loss looms

Merck & Co will buy Terns Pharmaceuticals, Inc., a clinical-stage oncology company, for $6.7 billion to pocket an investigational drug to treat a.

Read More
Novo Nordisk A/S and United Laboratories International Holdings Limited (TUL) mid-stage trials, held in China, helped in reducing average blood sugar levels by up to 2.16% in diabetic patients and trimmed weight by almost 10%, according to a statement.
Drugs Health Pharma

Novo, United’s trial drug cuts sugar levels by 2.16%, weight loss of 9.8%

HQ Team March 25, 2026: Novo Nordisk A/S and United Laboratories International Holdings Limited (TUL) mid-stage trials, held in China, helped in reducing.

Read More
Pfizer Inc. and France-based Valneva SE's investigational vaccine has shown 70% efficacy in preventing Lyme disease in individuals aged five and above.
Drugs Medical Pharma

Pfizer, Valneva’s experimental Lyme disease vaccine shows 70% efficacy

HQ Team March 25, 2026: Pfizer Inc. and France-based Valneva SE‘s investigational vaccine has shown 70% efficacy in preventing Lyme disease in individuals.

Read More
Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for $2 billion, according to a statement. 
Drugs Medical Pharma

Gilead Sciences to acquire US-based Ouro Medicines for up to $2 billion 

Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for.

Read More
Novartis AG has agreed to buy an investigational oral medicine of Pikavation Therapeutics, a subsidiary of privately-held Synnovation Therapeutics, to treat breast cancer, for a deal worth $3 billion.
Drugs Medical Pharma

Novartis AG to buy experimental oral drug of Pikavation for $3 billion

Novartis AG has agreed to buy an investigational oral medicine of Pikavation Therapeutics, a subsidiary of privately-held Synnovation Therapeutics, to treat breast cancer, for.

Read More